MeiraGTx Holdings plc Announces \$100 Million+ Ordinary Share Offering

Key Details of the Offering and Material Agreements

MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical-stage gene therapy company, has announced a significant capital raise through a public offering of its ordinary shares. The company entered into a material definitive underwriting agreement on April 16, 2026 with BofA Securities, Inc. and Goldman Sachs & Co. LLC, acting as underwriters. The offering involves the issuance and sale of 11,111,111 ordinary shares at a price of \$9.00 per share, resulting in gross proceeds of approximately \$100 million before underwriting discounts, commissions, and expenses.

Key Points of the Transaction

• Offering Size: 11,111,111 ordinary shares are being offered and sold by MeiraGTx Holdings plc.
• Offering Price: \$9.00 per share.
• Underwriting Discount: \$0.54 per share, resulting in net proceeds to the company of \$8.46 per share.
• Underwriters: BofA Securities, Inc. and Goldman Sachs & Co. LLC are the lead underwriters. Raymond James & Associates, Inc. is also participating.
• Expected Closing Date: April 17, 2026, subject to customary closing conditions.
• Exchange Listing: The shares are listed on the Nasdaq Global Select Market under the symbol “MGTX”.

Important Information for Shareholders

• Potential Share Dilution: The issuance of a significant number of new shares will dilute existing shareholders. This is a key consideration for investors as it can affect share value, earnings per share, and voting power.
• Use of Proceeds: The company will use the net proceeds from this offering as specified in the prospectus. While the specific use is not detailed in the 8-K, such large capital raises are typically used for research and development activities, working capital, or other general corporate purposes, which could support pipeline growth and business expansion.
• Lock-Up Agreement: MeiraGTx’s directors and executive officers have signed agreements restricting the sale or transfer of the company’s shares for a period of 45 days from the date of the prospectus, subject to certain exceptions (e.g., transfers among affiliates, sales under Rule 10b5-1 plans, or in connection with a change of control). This lock-up could help support the share price in the short term.
• Legal Opinion: Walkers (Cayman) LLP, the company’s Cayman Islands counsel, has provided a legal opinion that the ordinary shares to be issued are validly issued, fully paid, and non-assessable.
• No Material Adverse Change: The underwriting agreement contains the company’s representation that, except as disclosed, there has been no material adverse change in the company’s condition, business, or prospects since the last reported period.

Forward-Looking Statements and Risks

The company’s report contains forward-looking statements relating to the completion of the offering, expected use of proceeds, and sufficiency of cash to fund operations. These statements are based on management’s current expectations and are subject to known and unknown risks, such as market conditions, satisfaction of closing conditions, and risks related to product development. Investors should note that actual results could differ materially from these projections. MeiraGTx disclaims any obligation to update these statements unless required by law.

Underwriting Details

Underwriters’ Participation:

• BofA Securities, Inc.: 5,000,000 shares
• Goldman Sachs & Co. LLC: 5,000,000 shares
• Raymond James & Associates, Inc.: 1,111,111 shares

Net Proceeds: Before expenses, the total net proceeds to the company are approximately \$93,333,333.

Regulatory and Compliance Notes

• The shares are offered under an effective shelf registration statement (Form S-3, Registration No. 333-276183) and a related prospectus supplement filed with the SEC.
• The company and its accountants confirm compliance with all relevant U.S. and Cayman Islands laws and regulations, including Sarbanes-Oxley, Nasdaq rules, and the Investment Company Act.
• The company asserts effective internal controls and that there has been no material weakness since the latest audited period.

Potential Share Price Impact

This public offering is highly price sensitive for several reasons:

• Dilution: The issuance of new shares increases the total share count, which may dilute the value of existing shares.
• Capital Raise: The infusion of capital strengthens the company’s balance sheet, providing resources for strategic projects, clinical trials, or other growth initiatives.
• Market Perception: The participation of leading underwriters (BofA, Goldman Sachs, Raymond James) may be viewed positively by the market as a sign of institutional support.
• Lock-up Agreements: Temporary restrictions on insider selling can reduce short-term selling pressure.

Shareholder Considerations

• Shareholders are encouraged to review the company’s filings, including the prospectus supplement, to understand the terms of the offering and the intended use of proceeds.
• Investors should monitor for any material adverse changes or updates from the company as the offering closes and proceeds are deployed.
• The company has made customary indemnification arrangements with the underwriters regarding disclosures in the offering documents.

Summary

MeiraGTx Holdings plc’s \$100 million+ ordinary share offering is a major development for the company and its shareholders. The transaction brings significant new capital, may impact the share price due to dilution, and underscores the company’s ongoing efforts to fund its operations and future growth. Investors should consider the short-term and long-term implications of this capital raise, including the potential for new projects, pipeline advancement, and changes in shareholder composition.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The company’s forward-looking statements involve risks and uncertainties. Actual results may differ materially from those anticipated. The author assumes no responsibility for investment actions taken by readers.

View MeiraGTx Holdings plc Historical chart here